ReviewFrontiers in immunology2026
A review of the impact of isolated antiphospholipid antibody positivity on pregnancy outcomes and clinical management strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This review summarizes the current evidence on the impact of isolated antiphospholipid antibody positivity (IAAP) on pregnancy outcomes. It analyzes risk differentials across antibody subtypes, synthesizes the underlying pathophysiological mechanisms, and reviews existing treatment strategies to inform clinical practice. Methods: A comprehensive review was conducted. Data were retrieved and analyzed from relevant observational, cohort, and randomized controlled trials, both domestically and internationally, focusing on clinical outcomes, risk stratification, pathogenic mechanisms, and the management of IAAP. Results: Positive antiphospholipid antibodies alone constitute a risk factor for adverse pregnancy outcomes. The pathological mechanisms linking IAAP to adverse outcomes involve multiple processes, including thrombosis, trophoblast dysfunction, and complement activation. Clinical management should involve risk stratification based on antibody profiles. For high-risk patients, a combination therapy of low-molecular-weight heparin and aspirin is recommended, with hydroxychloroquine as a potential adjuvant. Standardization of antibody testing and optimal timing for dynamic monitoring remain areas needing improvement. Conclusion and future perspectives: IAAP is associated with an increased risk of adverse pregnancy outcomes. Further research is needed to determine whether the presence of these antibodies may contribute to the development of autoimmune disease. Future research should focus on developing precise risk-stratification models that integrate antibody type, titer, and clinical features. Prospective studies are warranted to establish individualized monitoring and intervention protocols, ultimately contributing to an evidence-based clinical consensus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.